Advertisement

Production of Anti-c-Myc Monoclonal Antibody Inhibiting DNA Binding of c-Myc and Max Dimer by Epitope Peptide–CpG-DNA–Liposome Complex Without Carriers

  • Byoung Kwon Park
  • Avishekh Gautam
  • Sony Maharjan
  • Su In Lee
  • Younghee Lee
  • Hyung-Joo KwonEmail author
Article
  • 94 Downloads

Abstract

The c-Myc protein is diversely involved in normal cellular function, and its deregulation has been implicated in several cancers. Therefore, c-Myc is a validated target for anti-cancer therapeutics. Here, we developed a monoclonal antibody specific to an epitope involved in the protein–protein interaction and DNA binding of c-Myc. We selected two candidate epitopes based on the antigenicity prediction and 3-D structure of c-Myc and successfully obtained a c-Myc-specific monoclonal IgG2a antibody clone. Based on the immunoprecipitation assay, the antibody recognized overexpressed c-Myc as well as endogenously expressed c-Myc in cell lines. The antibody co-immunoprecipitated Max showing that the antibody can recognize the c-Myc-Max heterodimer in solution. The results from the ELISA-based DNA binding assay revealed that treatment with the monoclonal antibody inhibits the binding activity of c-Myc. Therefore, we suggest that our anti-c-Myc monoclonal antibody can be used as a starting material for the development of an anti-cancer drug targeting c-Myc.

Keywords

B cell epitope MAb Max C-Myc 

Notes

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning in the Republic of Korea (NRF-2015R1A2A2A01007209, 2014M3C1A3051473, 2016M3A9B6916708, 2009-0093812). Byoung Kwon Park was supported by the Hallym University Postdoctoral Fellowship Program of 2017 (HLM-PF-2017-0001).

Compliance with Ethical Standards

Conflict of interest

Byoung Kwon Park, Avishekh Gautam, Sony Maharjan, Su In Lee, Younghee Lee and Hyung-Joo Kwon confirm that this article content has no conflicts of interest.

Research Involving Human and Animal Rights

All institutional and national guidelines for the care and use of laboratory animals were followed. All procedures performed in studies involving animals were approved by the institutional animal ethical committee. This article does not include any studies using human subjects.

Informed Consent

The article does not contain any studies in patients by any of the authors.

References

  1. Avignolo C, Bagnasco L, Biasotti B et al (2008) Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 22(4):1237–1245CrossRefGoogle Scholar
  2. Berg T (2011) Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 348:139–149Google Scholar
  3. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998):1211–1217CrossRefGoogle Scholar
  4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121–1124CrossRefGoogle Scholar
  5. Conacci-Sorrell M, McFerrin L, Eisenman RN (2014) An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4(1):a014357CrossRefGoogle Scholar
  6. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19(1):1–11CrossRefGoogle Scholar
  7. Dang CV (2012) MYC on the path to cancer. Cell 149(1):22–35CrossRefGoogle Scholar
  8. Guillard S, Minter RR, Jackson RH (2015) Engineering therapeutic proteins for cell entry: the natural approach. Trends Biotechnol 33(3):163–171CrossRefGoogle Scholar
  9. Hönnemann J, Sanz-Moreno A, Wolf E, Eilers M, Elsässer HP (2012) Miz1 is a critical repressor of cdkn1a during skin tumorigenesis. PLoS ONE 7(4):e34885CrossRefGoogle Scholar
  10. Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43:11–21CrossRefGoogle Scholar
  11. Kiessling A, Sperl B, Hollis A, Eick D, Berg T (2006) Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 13(7):745–751CrossRefGoogle Scholar
  12. Kim D, Kwon S, Rhee JW et al (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12:29CrossRefGoogle Scholar
  13. Kwon S, Choi KC, Kim YE et al (2014) Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res 74(14):3844–3856CrossRefGoogle Scholar
  14. Marschall AL, Zhang C, Frenzel A et al (2014) Delivery of antibodies to the cytosol: debunking the myths. MAbs 6(4):943–956CrossRefGoogle Scholar
  15. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193–205CrossRefGoogle Scholar
  16. Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: marvelously complex. Adv Cancer Res 84:81–154CrossRefGoogle Scholar
  17. Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34(2):101–109CrossRefGoogle Scholar
  18. Park BK, Lee SI, Lee Y et al (2016) Effect of a monoclonal antibody against relaxin-2 on cancer cell growth inhibition. Appl Biol Chem 59(5):739–746CrossRefGoogle Scholar
  19. Posternak V, Cole MD (2016) Strategically targeting MYC in cancer. F1000Res.  https://doi.org/10.12688/f1000research.7879.1.eCollection2016 Google Scholar
  20. Prochownik EV, Vogt PK (2010) Therapeutic targeting of Myc. Genes Cancer 1(6):650–659CrossRefGoogle Scholar
  21. Sakamuro D, Prendergast GC (1999) New Myc-interacting proteins: a second Myc network emerges. Oncogene 18(19):2942–2954CrossRefGoogle Scholar
  22. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287CrossRefGoogle Scholar
  23. Sheiness D, Bishop JM (1979) DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 31(2):514–521Google Scholar
  24. Sohn WJ, Kim D, Lee KW et al (2007) Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol 44(13):3273–3282CrossRefGoogle Scholar
  25. Soucek L, Jucker R, Panacchia L et al (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62(12):3507–3510Google Scholar
  26. Stellas D, Szabolcs M, Koul S et al (2014) Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst 106(12).  https://doi.org/10.1093/jnci/dju320
  27. Varmus HE (1984) The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553–612CrossRefGoogle Scholar
  28. Vogt PK (2012) Retroviral oncogenes: a historical primer. Nat Rev Cancer 12(9):639–648CrossRefGoogle Scholar
  29. Wang H, Hammoudeh DI, Follis AV et al (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6(9):2399–2408CrossRefGoogle Scholar
  30. Wang J, Ma X, Jones HM et al (2014) Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J Transl Med 12:226CrossRefGoogle Scholar
  31. Wiese KE, Walz S, von Eyss B et al (2013) The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 3(12):a014290CrossRefGoogle Scholar
  32. Yokoyama WM, Christensen M, Santos GD, Miller D (2006) Production of monoclonal antibodies. Curr Protoc Immunol.  https://doi.org/10.1002/0471142735.im0205s74 Google Scholar
  33. Zhang W, Kater AP, Widhopf GF 2nd et al (2010) B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 107(44):18956–18960CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Center for Medical Science Research, College of MedicineHallym UniversityChuncheonRepublic of Korea
  2. 2.Department of Microbiology, College of MedicineHallym UniversityChuncheonRepublic of Korea
  3. 3.Department of Biochemistry, College of Natural SciencesChungbuk National UniversityCheongjuRepublic of Korea

Personalised recommendations